SG11201404177PA - Mica binding agents - Google Patents
Mica binding agentsInfo
- Publication number
- SG11201404177PA SG11201404177PA SG11201404177PA SG11201404177PA SG11201404177PA SG 11201404177P A SG11201404177P A SG 11201404177PA SG 11201404177P A SG11201404177P A SG 11201404177PA SG 11201404177P A SG11201404177P A SG 11201404177PA SG 11201404177P A SG11201404177P A SG 11201404177PA
- Authority
- SG
- Singapore
- Prior art keywords
- binding agents
- mica binding
- mica
- agents
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261595902P | 2012-02-07 | 2012-02-07 | |
US201261625841P | 2012-04-18 | 2012-04-18 | |
PCT/EP2013/052439 WO2013117647A1 (en) | 2012-02-07 | 2013-02-07 | Mica binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201404177PA true SG11201404177PA (en) | 2014-08-28 |
Family
ID=47714068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201404177PA SG11201404177PA (en) | 2012-02-07 | 2013-02-07 | Mica binding agents |
Country Status (11)
Country | Link |
---|---|
US (2) | US10577416B2 (en) |
EP (1) | EP2812027A1 (en) |
JP (1) | JP6405242B2 (en) |
CN (1) | CN104244977A (en) |
AU (1) | AU2013218017B2 (en) |
BR (1) | BR112014019611A2 (en) |
CA (1) | CA2862101A1 (en) |
IL (1) | IL233793B (en) |
RU (1) | RU2656183C2 (en) |
SG (1) | SG11201404177PA (en) |
WO (1) | WO2013117647A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102017070B1 (en) | 2011-09-30 | 2019-09-02 | 다나-파버 캔서 인스티튜트 인크. | Therapeutic peptides |
AU2013218017B2 (en) | 2012-02-07 | 2017-12-07 | Innate Pharma | MICA binding agents |
US10851148B2 (en) | 2013-03-15 | 2020-12-01 | Novelogics Biotechnology, Inc. | Antibodies to MICA and MICB proteins |
CN105142668B (en) * | 2013-03-15 | 2018-04-27 | 达纳-法伯癌症研究院公司 | Therapeutic peptide |
MX371187B (en) | 2013-12-06 | 2020-01-22 | Dana Farber Cancer Inst Inc | Therapeutic peptides. |
EP3925973A1 (en) | 2014-03-14 | 2021-12-22 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
LT3227311T (en) * | 2014-12-05 | 2022-02-25 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands |
EP3270937A4 (en) | 2015-03-26 | 2018-09-12 | The Trustees Of Dartmouth College | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
JP6944925B2 (en) | 2015-07-24 | 2021-10-06 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | How to detect tissue-infiltrating NK cells |
RU2747296C2 (en) * | 2015-12-04 | 2021-05-04 | Дана-Фарбер Кэнсер Инститьют, Инк. | Vaccination using the alpha 3 domain of mica/b for cancer treatment |
WO2017147247A1 (en) * | 2016-02-23 | 2017-08-31 | Pires Eusebio S | Anti-sas1b antibodies and methods of use |
EP3430047A1 (en) | 2016-03-15 | 2019-01-23 | Innate Pharma | Anti-mica antibodies |
CN107779433A (en) * | 2016-08-30 | 2018-03-09 | 天津市康婷生物工程有限公司 | Easily stimulate NK cells propagation and the feeder layer preparation method of differentiation |
EP3529280A4 (en) * | 2016-10-19 | 2020-04-22 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
CN107964041B (en) * | 2016-10-20 | 2023-08-01 | 中国科学院广州生物医药与健康研究院 | High stability and high affinity DMIC and its preparing process |
JP2019535250A (en) | 2016-10-29 | 2019-12-12 | ジェネンテック, インコーポレイテッド | Anti-MIC antibody and method of use |
EP3559042A4 (en) * | 2016-12-22 | 2020-11-25 | Icahn School of Medicine at Mount Sinai | Anti-lilrb3 antibodies and methods of use thereof |
WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
US11421032B2 (en) | 2017-05-22 | 2022-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for inhibition of MICA/B shedding |
BR112019027353A2 (en) * | 2017-07-10 | 2020-07-14 | Innate Pharma | agents, antibody, pharmaceutical composition, kits, lymphocyte modulation method, in vitro lymphocyte activity modulation method and composition |
EP3692068B1 (en) * | 2017-10-06 | 2022-12-07 | Innate Pharma | Restoration of t cell activity via the cd39/cd73 axis |
WO2019183551A1 (en) * | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
WO2020028428A2 (en) * | 2018-07-31 | 2020-02-06 | Pdi Therapeutics, Inc. | Anti-mica/b antibodies that block mica/b shedding and methods of use |
WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
US20220288225A1 (en) * | 2019-08-23 | 2022-09-15 | Northwestern University | Materials and methods for activating antigen-specific t cell responses |
EP4069748A4 (en) * | 2019-12-05 | 2023-11-15 | Vycellix, Inc. | Modulators of the immune escape mechanism for universal cell therapy |
CN111471099B (en) * | 2020-03-31 | 2022-04-12 | 长沙学院 | MICA extracellular domain mutant and screening method thereof, scFv-MICA fusion antibody and preparation method and application thereof |
CN111718416B (en) * | 2020-06-25 | 2022-04-01 | 菲鹏生物股份有限公司 | Anti-thioredoxin antibody, application thereof and diagnostic kit |
CN116547301A (en) | 2020-08-10 | 2023-08-04 | 先天制药公司 | Cell surface MICA and MICB detection using antibodies |
CN112694532B (en) * | 2021-01-12 | 2023-04-18 | 倍而达药业(苏州)有限公司 | Antibody against Siglec-15 or antigen binding fragment thereof and application |
CN115611982A (en) * | 2021-07-14 | 2023-01-17 | 浙江大学 | Monoclonal antibody resisting human MICA/B alpha 3 region and application thereof |
CN114369162B (en) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | Antibodies and uses thereof |
CN114369161B (en) * | 2021-12-28 | 2023-06-23 | 合肥天港免疫药物有限公司 | MICA antibodies and uses thereof |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
WO1996030511A1 (en) * | 1995-03-29 | 1996-10-03 | The Immunogenetics Research Foundation Incorporated | Polymorphic and multicopy members of mhc gene families |
EP0937258A2 (en) | 1996-10-29 | 1999-08-25 | Fred Hutchinson Cancer Research Center, Inc. | Cell stress regulated human mhc class i gene |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2270148A3 (en) | 1999-04-09 | 2011-06-08 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7771718B2 (en) | 2002-04-22 | 2010-08-10 | Fred Hutchinson Cancer Research Center | Soluble MIC polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
JP2008504002A (en) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Neonatal Fc receptor (FcRn) binding polypeptide variants, dimeric Fc binding proteins, and methods related thereto |
US7521542B2 (en) | 2004-05-10 | 2009-04-21 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
EP1888638A2 (en) | 2005-06-03 | 2008-02-20 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
DK2573114T3 (en) | 2005-08-10 | 2016-07-04 | Macrogenics Inc | The identification and production of antibodies with variant Fc regions, and methods of using same |
US20070248607A1 (en) | 2005-11-03 | 2007-10-25 | Thomas Spies | Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells |
FR2894982A1 (en) | 2005-12-16 | 2007-06-22 | Lab Francais Du Fractionnement | Preparation of antibodies selective for activating Fc receptors, useful for treatment of tumors and viral or bacterial infections, by replacing specific histidine residues in the Fc region of a monoclonal antibody |
CA2637254A1 (en) | 2006-01-17 | 2007-07-26 | Biolex Therapeutics, Inc. | Compositions and methods for humanization and optimization of n-glycans in plants |
CA2644903A1 (en) | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
EP2021029B1 (en) | 2006-05-26 | 2014-06-11 | MacroGenics, Inc. | Humanized fc gamma riib-specific antibodies and methods of use thereof |
EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
CA2665090A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating mica-related disorders |
EP3187507A1 (en) * | 2007-04-23 | 2017-07-05 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by erp5 |
EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
DK2654780T3 (en) | 2010-12-23 | 2017-04-10 | Janssen Biotech Inc | ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS |
KR102017070B1 (en) | 2011-09-30 | 2019-09-02 | 다나-파버 캔서 인스티튜트 인크. | Therapeutic peptides |
AU2013218017B2 (en) | 2012-02-07 | 2017-12-07 | Innate Pharma | MICA binding agents |
EP3430047A1 (en) | 2016-03-15 | 2019-01-23 | Innate Pharma | Anti-mica antibodies |
-
2013
- 2013-02-07 AU AU2013218017A patent/AU2013218017B2/en not_active Ceased
- 2013-02-07 JP JP2014556052A patent/JP6405242B2/en active Active
- 2013-02-07 US US14/377,274 patent/US10577416B2/en not_active Expired - Fee Related
- 2013-02-07 BR BR112014019611A patent/BR112014019611A2/en not_active Application Discontinuation
- 2013-02-07 RU RU2014131317A patent/RU2656183C2/en active
- 2013-02-07 EP EP13704064.8A patent/EP2812027A1/en not_active Ceased
- 2013-02-07 CA CA2862101A patent/CA2862101A1/en not_active Abandoned
- 2013-02-07 SG SG11201404177PA patent/SG11201404177PA/en unknown
- 2013-02-07 CN CN201380017820.5A patent/CN104244977A/en active Pending
- 2013-02-07 WO PCT/EP2013/052439 patent/WO2013117647A1/en active Application Filing
-
2014
- 2014-07-24 IL IL233793A patent/IL233793B/en active IP Right Grant
-
2020
- 2020-02-28 US US16/804,705 patent/US20200299380A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2862101A1 (en) | 2013-08-15 |
EP2812027A1 (en) | 2014-12-17 |
WO2013117647A1 (en) | 2013-08-15 |
JP6405242B2 (en) | 2018-10-17 |
US20200299380A1 (en) | 2020-09-24 |
JP2015508757A (en) | 2015-03-23 |
IL233793B (en) | 2020-04-30 |
RU2014131317A (en) | 2016-03-27 |
IL233793A0 (en) | 2014-09-30 |
AU2013218017A2 (en) | 2014-10-16 |
US10577416B2 (en) | 2020-03-03 |
AU2013218017A1 (en) | 2014-09-11 |
US20150191542A1 (en) | 2015-07-09 |
CN104244977A (en) | 2014-12-24 |
RU2656183C2 (en) | 2018-05-31 |
BR112014019611A2 (en) | 2017-06-27 |
AU2013218017B2 (en) | 2017-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL233793B (en) | Mica binding agents | |
IL237220A0 (en) | Kir3dl2 binding agents | |
HK1208619A1 (en) | Novel ha binding agents ha | |
HK1208687A1 (en) | Rspo3 binding agents and uses thereof rspo3 | |
EP2934531A4 (en) | Combination | |
GB2506862B (en) | Book | |
AP2015008266A0 (en) | 1L-18 binding molecules | |
GB201209880D0 (en) | Applicators | |
PL2928935T3 (en) | Binders | |
EP2911673A4 (en) | Combination | |
GB201200707D0 (en) | Composition | |
ZA201409119B (en) | Polymer-nsaid conjugate | |
EP2868485A4 (en) | Binder | |
EP2878295A4 (en) | Composition | |
PL2928936T3 (en) | Binder | |
EP2906215A4 (en) | Combinations | |
EP2837670A4 (en) | Fluorobiphenyl-containing composition | |
EP2910537A4 (en) | Gas-generating-agent composition | |
EP2910538A4 (en) | Gas-generating-agent composition | |
GB2500883B (en) | Improved saw-horse | |
EP2925728A4 (en) | Combination | |
GB201200563D0 (en) | Binding molecule | |
GB201214293D0 (en) | Binding surfaces | |
PL2641462T3 (en) | Binding device | |
GB201217550D0 (en) | Stoarage book |